Stay updated on STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdded primary peritoneal carcinoma to the conditions and included the Genetic and Rare Diseases Information Center under resources. Revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check2 days agoChange DetectedRevision: v3.4.1 is displayed in place of v3.4.0, a minor version label update that does not affect study content or available actions for users.SummaryDifference0.1%

- Check10 days agoChange DetectedAdded a Show glossary option and updated the QC status line to 'Last Update Submitted that Met QC Criteria.' Minor capitalization changes for 'No FEAR Act Data' and a site revision label 'Revision: v3.4.0' were also applied.SummaryDifference0.2%

- Check17 days agoChange DetectedThe page now displays a 'Last Update Posted' timestamp field, and the previous 'Last Update Posted (Estimated)' label has been removed. This is a UI/metadata update rather than a change to study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check24 days agoChange DetectedThe page's revision label updated from v3.3.3 to v3.3.4. No study details or content were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedIntroduced a new Locations section listing study sites in Florida, Pennsylvania, Tennessee, Virginia, and Wisconsin. The footer will show Revision: v3.3.3 and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.6%

Stay in the know with updates to STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.